Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $250.00 Price Target at Wells Fargo & Company

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective raised by equities research analysts at Wells Fargo & Company from $235.00 to $250.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 30.45% from the company’s previous close.

JAZZ has been the topic of a number of other reports. Robert W. Baird upped their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Piper Sandler reissued an “overweight” rating and issued a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. UBS Group reiterated a “neutral” rating and set a $188.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Royal Bank Of Canada set a $194.00 price objective on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research note on Monday, November 17th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Fourteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $208.60.

Jazz Pharmaceuticals Stock Up 10.2%

NASDAQ JAZZ traded up $17.81 during mid-day trading on Wednesday, reaching $191.64. The stock had a trading volume of 1,912,962 shares, compared to its average volume of 1,029,824. The stock has a market cap of $11.64 billion, a PE ratio of -31.32, a price-to-earnings-growth ratio of 0.93 and a beta of 0.26. Jazz Pharmaceuticals has a 1 year low of $95.49 and a 1 year high of $194.83. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The company has a fifty day moving average price of $168.08 and a 200 day moving average price of $150.27.

Insider Buying and Selling

In related news, SVP Mary Elizabeth Henderson sold 2,238 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the sale, the senior vice president owned 19,508 shares in the company, valued at approximately $3,306,801.08. This represents a 10.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Patricia Carr sold 4,660 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $171.20, for a total transaction of $797,792.00. Following the completion of the sale, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. The trade was a 39.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Large investors have recently modified their holdings of the business. Farther Finance Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 234 shares during the period. Hilltop National Bank purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $36,000. Hantz Financial Services Inc. increased its stake in Jazz Pharmaceuticals by 471.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 297 shares in the last quarter. LRI Investments LLC purchased a new position in Jazz Pharmaceuticals in the 4th quarter worth $38,000. Finally, Danske Bank A S purchased a new position in shares of Jazz Pharmaceuticals in the third quarter worth about $40,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 beat — Jazz reported Q4 revenue of $1.20B and EPS of $6.64, both topping Street estimates, and closed 2025 with record total revenues of $4.3B. Press Release
• Positive Sentiment: Product momentum — Management highlighted strong commercial performance: Xywav reached $1.7B (+12% YoY), Epidiolex $1.1B (+9% YoY) and Modeyso delivered $37M in its first full quarter, supporting top-line growth. Product Highlights
• Positive Sentiment: 2026 revenue guide — Jazz issued 2026 total revenue guidance of $4.25B–$4.50B and management reiterated progress on rare-disease and oncology launches (including an expected sBLA RTOR filing for zanidatamab). This outlook is a near-term catalyst. Revenue Outlook
• Positive Sentiment: Analyst upgrade — Bank of America raised its price target to $275 and reiterated a Buy rating, signaling significant analyst upside versus current levels and likely supporting investor demand. Benzinga
• Neutral Sentiment: Investor materials posted — The full earnings call transcript and the Q4 slide deck are available for review (useful for modeling product/launch assumptions and margin drivers). Earnings Transcript Presentation
• Neutral Sentiment: Street analysis — Coverage pieces (Zacks, Seeking Alpha previews) compare metrics to estimates and highlight what to watch (oncology launches, sBLA timing) — useful but not new surprises. Zacks Analysis
• Negative Sentiment: Margin and profitability notes — Despite the beat, some filings/coverage flag a negative net margin (reported -8.86% in the quarter) and other accounting/expense dynamics that could pressure reported profitability or require clarification from management. MarketBeat Earnings Summary

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.